文献速递淋巴瘤

同步中枢神经系统与全身受累的弥漫大B细胞淋巴瘤结局由CNS疾病决定:澳大利亚淋巴瘤联盟合作研究

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
PubMed 文献 · Br J Haematol · 2019-06-24

该回顾性研究纳入10个澳大利亚和英国中心的80例同步CNS与全身受累的初治DLBCL患者,96%有结外全身病变。结局主要由CNS疾病控制决定,CNS复发累积发生率42%,非CNS复发21%。

核心结论

  • 充分控制CNS疾病最为关键,最好通过强化CNS导向的诱导治疗实现。

研究设计与样本

  • 回顾性分析10个澳大利亚和英国中心治疗的80例同步CNS与全身受累的初治DLBCL患者。

主要发现

  • 96%患者有结外全身病变。
  • 超分割或输注式全身治疗对比R-CHOP:2年OS均为49%。

临床怎么用

  • 对于同步CNS与全身受累的DLBCL,采用包含静脉阿糖胞苷和大剂量甲氨蝶呤的CNS强化诱导策略可能改善生存。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

De novo diffuse large B-cell lymphoma (DLBCL) presenting with synchronous central nervous system (CNS) and systemic disease (synDLBCL) is not well described and is excluded from clinical trials. We performed a retrospective analysis of 80 synDLBCL patients treated across 10 Australian and UK centres. Of these patients, 96% had extranodal systemic disease. CNS-directed treatment with combination intravenous cytarabine and high-dose methotrexate ("CNS-intensive") (n = 38) was associated with favourable survival outcomes compared with "CNS-conservative" strategies such as intravenous high-dose methotrexate monotherapy, intrathecal therapy and/or radiotherapy (2-year progression-free survival [PFS] 50% vs. 31%, P = 0·006; 2-year overall survival [OS] 54% vs. 44%, P = 0·037). Outcomes were primarily dictated by the ability to control the CNS disease, with 2-year cumulative CNS relapse incidence of 42% and non-CNS relapse 21%. Two-year OS for CNS-relapse patients was 13% vs. 36% for non-CNS relapses (P = 0·02). Autologous stem cell transplantation as consolidation (n = 14) was not observed to improve survival in those patients who received CNS-intensive induction when matched for induction outcomes (2-year PFS 69% vs. 56%, P = 0·99; 2-year OS 66% vs. 56%, P = 0·98). Hyperfractionated or infusional systemic treatment did not improve survival compared to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) (2-year OS 49% for both groups). Our study suggests that adequate control of the CNS disease is paramount and is best achieved by intensive CNS-directed induction.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wight JC, Yue M, Keane C, et al. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. Br J Haematol. 2019. PMID: 31236941. doi:10.1111/bjh.16064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。